Recent Updates
Recently added Catalysts
TARA Positive Sentiment

STARBORN - 1 Clinical Trial Interim Update

Wednesday, November 19, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article provides an interim update on the STARBORN - 1 clinical trial, focusing on TARA-002, which has shown significant results in treating patients with LMS. The data update reveals promising outcomes before and after treatment in two patients. This advance is highlighted by statements from company executives and involved researchers, indicating a hopeful outlook on TARA-002's efficacy.
Price reaction · baseline $6.75 (2025-11-18 close) · hit after-hours · 1 other TARA headline(s) in the window, move may be shared
day 0 close
-0.6%
day 1
-4.6%
day 3 · peak
+9.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • TARA-002 demonstrated meaningful results in LMS patients.
  • The interim data update from the STARBORN - 1 study shows promise.
  • Excitement about the potential of TARA-002 in treating patients.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+147%
120-day peak, hindsight
Typical move
11.7%
average across 4 past catalysts
Cash runway
~21 mo
Low dilution risk
Lead asset
Choline Chloride
Phase 2 · Choline Deficiency

Full Press Release Details

STARBORN - 1 Clinical Trial Interim Update November 19, 2025
TARA - 002 IN LMS Interim STARBORN - 1 Data Update and OK - 432 Data Review
TARA - 002 Demonstrated Meaningful Results in LMs Patients Treated in the STARBORN - 1 Study BEFORE AFTER BEFORE AFTER 17 Medical photography from 2 patients pre - and post - treatment with TARA - 002 in STARBORN - 1 trial
Q&A 22 Jesse Shefferman Co - founder, Director, Chief Executive Officer Jacqueline Zummo, PhD Co - founder, Senior Vice President, Chief Scientific Operations Officer Jesse G.A. Jones, MD University of Alabama - Department of Neurosurgery and Radiology, and STARBORN - 1 study investigator

Frequently Asked Questions

What is STARBORN - 1?

STARBORN - 1 is a clinical trial studying the effects of TARA - 002.

What were the results for TARA - 002?

TARA - 002 showed significant outcomes for patients with LMs in the trial.

Who are the key figures in the STARBORN - 1 study?

Key figures include Jesse Shefferman and Jacqueline Zummo, PhD.

What date was the interim update released?

The interim update for STARBORN - 1 was released on November 19, 2025.

Where was the STARBORN - 1 study conducted?

The study was conducted at the University of Alabama's Department of Neurosurgery.

ShareAdd on Google
Tags: TARA Viatris Investor Conferences Healthcare LMS STARBORN-1 clinical trial biopharma
Last updated: Nov 19, 2025

Biotech snapshot

Cash runway
$162M liquidity · $8M/mo burn
~21 mo
Low dilution risk
Lead asset
Choline ChloridePhase 2
Choline Deficiency →

Catalyst track record

+147%
best trade around TARA's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for TARA.

See every catalyst's timing & PoA →